Mutations in the PARK2 gene, which encodes PARKIN, are the most frequent cause of autosomal recessive Parkinson's disease (PD). We report the generation of an induced pluripotent stem cell (iPSC) line from a 78-year-old patient carrying a compound heterozygous mutation (c.823C>T and EX6del) in the PARK2 gene. Skin fibroblasts were reprogrammed using the non-integrating Sendai virus technology to deliver OCT3/4, SOX2, c-MYC and KLF4 factors. The generated cell line CSC-44 exhibits expression of common pluripotency markers, in vitro differentiation into the three germ layers and normal karyotype. This iPSC line can be used to explore the association between PARK2 mutations and PD.
Pubmed ID: 29353703 RIS Download
Publication data is provided by the National Library of Medicine ® and PubMed ®. Data is retrieved from PubMed ® on a weekly schedule. For terms and conditions see the National Library of Medicine Terms and Conditions.
This polyclonal secondary targets IgG (H+L)
View all literature mentionsThis polyclonal targets IgY (IgG) (H+L)
View all literature mentionsThis polyclonal secondary targets IgG (H+L)
View all literature mentionsThis monoclonal targets β-Tubulin III
View all literature mentionsThis monoclonal targets Actin, α-Smooth Muscle
View all literature mentionsThis monoclonal targets alpha-Fetoprotein (AFP)
View all literature mentionsThis polyclonal targets Sendai Virus Sendai virus
View all literature mentionsThis monoclonal targets SSEA4
View all literature mentionsThis monoclonal targets TRA-1-81
View all literature mentionsThis monoclonal targets Nanog
View all literature mentionsThis monoclonal targets Oct-4 clone 10H11.2
View all literature mentions